Old Web
English
Sign In
Acemap
>
authorDetail
>
Dawn Gustafson
Dawn Gustafson
AbbVie
Medicine
Crohn's disease
Risankizumab
Diabetes mellitus
open label
4
Papers
7
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.
2021
Journal of Crohns & Colitis
Marc Ferrante
Brian G. Feagan
Julián Panés
Filip Baert
Edouard Louis
Olivier Dewit
Arthur Kaser
W Rachel Duan
Yinuo Pang
Wan-Ju Lee
Dawn Gustafson
Xiaomei Liao
Kori Wallace
Jasmina Kalabic
Geert R. DHaens
Show All
Source
Cite
Save
Citations (3)
OP27 Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s disease: Final results from the Phase 2 open-label extension study
2020
Journal of Crohns & Colitis
Marc Ferrante
Brian G. Feagan
Julià Panés
F Baert
Edouard Louis
Olivier Dewit
Arthur Kaser
Weijiang (Rachel) Duan
Dawn Gustafson
Xiaomei Liao
Kori Wallace
Jasmina Kalabic
G D’Haens
Show All
Source
Cite
Save
Citations (4)
Tu1873 LONG-TERM SAFETY AND EFFICACY OF RISANKIZUMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE: FINAL RESULTS FROM THE PHASE 2 OPEN-LABEL EXTENSION STUDY
2020
Gastroenterology
Marc Ferrante
Brian G. Feagan
Julián Panés
Filip Baert
Edouard Louis
Olivier Dewit
Arthur Kaser
Weijiang (Rachel) Duan
Dawn Gustafson
Xiaomei Liao
Kori Wallace
Jasmina Kalabic
Geert R. DHaens
Show All
Source
Cite
Save
Citations (0)
OWE-05 Interim long-term safety/efficacy of risankizumab treatment in crohn’s disease patients from the open-label extension study
2019
Gut
Marc Ferrante
Julián Panés
F Baert
Edouard Louis
Arthur Kaser
Dawn Gustafson
David B. Hall
Wulf O. Böcher
Ivona Herichova
Xiaomei Liao
Kori Wallace
Jasmina Kalabic
G. R. D'Haens
Show All
Source
Cite
Save
Citations (0)
1